These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 23371292)

  • 61. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine.
    Mwenifumbo JC; Tyndale RF
    Pharmacogenomics; 2007 Oct; 8(10):1385-402. PubMed ID: 17979512
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration.
    Schoedel KA; Sellers EM; Palmour R; Tyndale RF
    Mol Pharmacol; 2003 Jan; 63(1):96-104. PubMed ID: 12488541
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Smoking behavior and related cancers: the role of CYP2A6 polymorphisms.
    Nakajima M
    Curr Opin Mol Ther; 2007 Dec; 9(6):538-44. PubMed ID: 18041664
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences.
    Chenoweth MJ; Ware JJ; Zhu AZX; Cole CB; Cox LS; Nollen N; Ahluwalia JS; Benowitz NL; Schnoll RA; Hawk LW; Cinciripini PM; George TP; Lerman C; Knight J; Tyndale RF;
    Addiction; 2018 Mar; 113(3):509-523. PubMed ID: 28921760
    [TBL] [Abstract][Full Text] [Related]  

  • 65. CYP2A6 genetic variation and potential consequences.
    Xu C; Goodz S; Sellers EM; Tyndale RF
    Adv Drug Deliv Rev; 2002 Nov; 54(10):1245-56. PubMed ID: 12406643
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Application of a pharmacokinetic/pharmacogenetic approach to assess the nicotine metabolic profile of smokers in the real-life setting.
    Fogli S; Saba A; Del Re M; Pistelli F; Aquilini F; Zucchi R; Palla A; Breschi MC; Carrozzi L; Danesi R
    J Pharm Biomed Anal; 2016 Nov; 131():208-213. PubMed ID: 27599351
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level.
    Strasser AA; Benowitz NL; Pinto AG; Tang KZ; Hecht SS; Carmella SG; Tyndale RF; Lerman CE
    Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):234-8. PubMed ID: 21212060
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption.
    Chenoweth MJ; Zhu AZ; Sanderson Cox L; Ahluwalia JS; Benowitz NL; Tyndale RF
    Pharmacogenet Genomics; 2014 Mar; 24(3):172-6. PubMed ID: 24448396
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of whole deletion of CYP2A6 on nicotine metabolism in humans.
    Zhang X; Ameno K; Ameno S; Kinoshita H; Kubota T; Kumihashi M; Mostofa J; Iwahashi K; Ijiri I
    Drug Chem Toxicol; 2002 May; 25(2):203-13. PubMed ID: 12024803
    [TBL] [Abstract][Full Text] [Related]  

  • 70. CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers.
    Chenoweth MJ; O'Loughlin J; Sylvestre MP; Tyndale RF
    Pharmacogenet Genomics; 2013 Apr; 23(4):232-5. PubMed ID: 23462429
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk.
    Tyndale RF; Sellers EM
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):548-52. PubMed ID: 11259349
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers.
    Chenoweth MJ; Novalen M; Hawk LW; Schnoll RA; George TP; Cinciripini PM; Lerman C; Tyndale RF
    Cancer Epidemiol Biomarkers Prev; 2014 Sep; 23(9):1773-82. PubMed ID: 25012994
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence.
    Malaiyandi V; Sellers EM; Tyndale RF
    Clin Pharmacol Ther; 2005 Mar; 77(3):145-58. PubMed ID: 15735609
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The role of CYP2A6 in the emergence of nicotine dependence in adolescents.
    Audrain-McGovern J; Al Koudsi N; Rodriguez D; Wileyto EP; Shields PG; Tyndale RF
    Pediatrics; 2007 Jan; 119(1):e264-74. PubMed ID: 17130279
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An LC-MS/MS method for concurrent determination of nicotine metabolites and the role of CYP2A6 in nicotine metabolite-mediated oxidative stress in SVGA astrocytes.
    Ande A; Earla R; Jin M; Silverstein PS; Mitra AK; Kumar A; Kumar S
    Drug Alcohol Depend; 2012 Sep; 125(1-2):49-59. PubMed ID: 22498344
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent.
    Ho MK; Mwenifumbo JC; Zhao B; Gillam EM; Tyndale RF
    Pharmacogenet Genomics; 2008 Jan; 18(1):67-75. PubMed ID: 18216723
    [TBL] [Abstract][Full Text] [Related]  

  • 77. New CYP2A6 gene deletion and conversion variants in a population of Black African descent.
    Mwenifumbo JC; Zhou Q; Benowitz NL; Sellers EM; Tyndale RF
    Pharmacogenomics; 2010 Feb; 11(2):189-98. PubMed ID: 20136358
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes.
    Ray R; Tyndale RF; Lerman C
    J Neurogenet; 2009; 23(3):252-61. PubMed ID: 19169923
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A LC-MS/MS method for concurrent determination of nicotine metabolites and role of CYP2A6 in nicotine metabolism in U937 macrophages: implications in oxidative stress in HIV + smokers.
    Jin M; Earla R; Shah A; Earla RL; Gupte R; Mitra AK; Kumar A; Kumar S
    J Neuroimmune Pharmacol; 2012 Mar; 7(1):289-99. PubMed ID: 21655912
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans.
    Nakajima M; Yamagishi S; Yamamoto H; Yamamoto T; Kuroiwa Y; Yokoi T
    Clin Pharmacol Ther; 2000 Jan; 67(1):57-69. PubMed ID: 10668854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.